This technology is an anti-influenza virus composition containing Ardisia japonica methanol extract as an active ingredient. It includes pharmaceutical compositions, health functional foods, food products, and feed compositions for the prevention and treatment of infection-related diseases such as influenza, colds, pharyngitis, bronchitis, and pneumonia, as well as methods for their preparation.
Vaccines, the cornerstone of flu prevention, are produced based on early-year predictions of winter strains, leading to reduced efficacy if the actual circulating virus differs from the vaccine antigen, and making rapid responses to unexpected novel viruses difficult. While the neuraminidase inhibitor oseltamivir was effective during the 2009 pandemic, its repeated use led to the emergence of resistant strains that spread globally, and it also has limited efficacy against influenza B viruses.
This technology blocks the initial stage of viral cell entry by having Ardisia japonica extract coat and mask hemagglutinin, a viral surface glycoprotein, preventing it from binding to cell receptors. It can utilize water, hexane, chloroform, ethyl acetate, or butyl alcohol fractions in addition to methanol extract, and targets a broad range of viruses including types A, B, and C, H1N1, and highly pathogenic H5N1. By targeting hemagglutinin rather than neuraminidase, it provides a natural infection-blocking solution effective against drug-resistant viruses, suitable for new antivirals, combination therapies, respiratory health supplements, and poultry feed additives for avian influenza.
N/A
